List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6483813/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
2	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationA. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
3	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. Aids, 2009, 23, 1743-1753.	1.0	200
4	Changes in the incidence and predictors of human immunodeficiency virus–associated dementia in the era of highly active antiretroviral therapy. Annals of Neurology, 2008, 63, 213-221.	2.8	167
5	Coinfection of Hepatitis C Virus with Human Immunodeficiency Virus and Progression to AIDS. Journal of Infectious Diseases, 1995, 172, 1503-1508.	1.9	158
6	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
7	The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids, 2011, 25, 1083-1091.	1.0	120
8	The Presence of Antiâ€Tat Antibodies Is Predictive of Longâ€Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIVâ€1 Seroconverters. Journal of Infectious Diseases, 2005, 191, 1321-1324.	1.9	118
9	Cancer risk among men with, or at risk of, HIV infection in southern Europe. Aids, 2000, 14, 553-559.	1.0	105
10	Effect of Maternal HIV and Malaria Infection on Pregnancy and Perinatal Outcome in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 289-294.	0.9	94
11	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
12	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. , 1999, 82, 334-337.		90
13	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88
14	HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ: British Medical Journal, 1994, 309, 1537-1542.	2.4	88
15	Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ: British Medical Journal, 1996, 313, 583-586.	2.4	88
16	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013, 144, 751-760.e2.	0.6	76
17	Cancer incidence in a cohort of human immunodeficiency virus seroconverters. , 1997, 79, 1004-1008.		73
18	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. Journal of Infectious Diseases, 1999, 180, 1018-1024.	1.9	66

#	Article	IF	CITATIONS
19	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Medicine, 2010, 7, e1000239.	3.9	54
20	Kaposi's Sarcoma in Transplant and HIV-infected Patients: An Epidemiologic Study in Italy and France. Transplantation, 2005, 80, 1699-1704.	0.5	50
21	Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Aids, 1995, 9, 597-604.	1.0	49
22	Higher rates of tripleâ€class virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
23	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985–2002. Journal of Infectious Diseases, 2007, 195, 525-534.	1.9	44
24	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
25	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
26	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. Annals of Internal Medicine, 2017, 166, 9.	2.0	41
27	Temporal Changes in the Rate of Progression to Death Among Italians With Known Date of HIV Seroconversion: Estimates of the Population Effect of Treatment. Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 65.	0.3	39
28	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	1.0	39
29	Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. Aids, 2001, 15, 1733-1736.	1.0	35
30	Incidence of Invasive Cervical Cancer in a Cohort of HIV-Seropositive Women Before and After the Introduction of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 377-380.	0.9	34
31	Viral causes of influenzaâ€like illness: Insight from a study during the winters 2004–2007. Journal of Medical Virology, 2009, 81, 2066-2071.	2.5	32
32	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals. Aids, 2014, 28, 1351-1356.	1.0	32
33	How Many HIV-Infected Individuals May Be Defined as Long-term Nonprogressors? A Report from the Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 243-248.	0.3	31
34	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	1.1	30
35	The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. Aids, 2004, 18, 2313-2318.	1.0	29
36	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Aids, 2000, 14, 1647-1653.	1.0	28

#	Article	IF	CITATIONS
37	Increased HIV incidence among men who have sex with men in Rome. Aids, 2005, 19, 1429-1431.	1.0	27
38	Epidemiological investigation of a varicella outbreak in an Italian prison. Scandinavian Journal of Infectious Diseases, 2008, 40, 943-945.	1.5	23
39	An outbreak of HIV-1 subtype G among Italian injecting drug users. Aids, 2007, 21, 1213-1215.	1.0	21
40	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	1.0	21
41	Homologous intrauterine insemination in controlled ovarian hyperstimulation cycles: A comparison among three different regimens. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 129, 155-161.	0.5	20
42	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
43	Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study. Lancet HIV,the, 2015, 2, e540-e549.	2.1	19
44	Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. Aids, 1997, 11, 461-467.	1.0	17
45	Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 15-21.	0.9	16
46	Estimating Minimum Adult HIV Prevalence: A Cross-Sectional Study to Assess the Characteristics of People Living with HIV in Italy. AIDS Research and Human Retroviruses, 2015, 31, 282-287.	0.5	16
47	Reference curves for <scp>CD</scp> 4 Tâ€cell count response to combination antiretroviral therapy in <scp>HIV</scp> â€lâ€infected treatmentâ€naà ve patients. HIV Medicine, 2017, 18, 33-44.	1.0	16
48	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. Epidemiology and Infection, 1998, 121, 369-376.	1.0	14
49	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. Aids, 2011, 25, 1041-1049.	1.0	14
50	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
51	Estimating the trend of the epidemic of drug use in Italy, 1985-89. Addiction, 1992, 87, 1643-1648.	1.7	12
52	Prevalence and Determinants of Herpes Simplex Virus Type 2 Infection in a Cohort of HIV-Positive Individuals in Italy. Sexually Transmitted Diseases, 2002, 29, 665-667.	0.8	12
53	Incidence of Invasive Cervical Cancer in a Cohort of HIV-Seropositive Women Before and After the Introduction of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 377-380	0.9	12
54	Declining prevalence of HIV infection among injecting drug users entering drug treatment in Italy: 1990–1991. European Journal of Epidemiology, 1993, 9, 663-666.	2.5	11

#	Article	IF	CITATIONS
55	Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. Aids, 2001, 15, 133-135.	1.0	11
56	Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. Journal of Medical Virology, 2003, 69, 182-187.	2.5	9
57	Immunologic Response to Highly Active Antiretroviral Therapy and Mortality Reduction in a Cohort of Human Immunodeficiency Virus–Positive Persons in Mozambique. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1128-1132.	0.6	8
58	Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. European Journal of Epidemiology, 1998, 14, 41-47.	2.5	7
59	The effect of aging on the incidence of Kaposi's sarcoma among HIV-positive individuals with known dates of seroconversion. International Journal of Cancer, 2003, 104, 251-254.	2.3	7
60	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
61	No Protective Effect of Acyclovir on HIV Disease Progression in a Cohort of Hsv-2–HIV-Infected Individuals. Antiviral Therapy, 2002, 7, 289-291.	0.6	7
62	Targeting Candidates for Directly Administered Highly Active Antiretroviral Therapy: Benefits Observed in HIV-Infected Injecting Drug Users in Residential Drug-Rehabilitation Facilities. AIDS Patient Care and STDs, 2011, 25, 359-364.	1.1	6
63	Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group. European Journal of Epidemiology, 1999, 15, 317-322.	2.5	5
64	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
65	Temporal Trend in the Level of 90K Glycoprotein after HIV Seroconversion among Persons Coinfected with Hepatitis C Virus. Infection, 2005, 33, 101-102.	2.3	3
66	People living with undiagnosed HIV infection and a low CD4 count: estimates from surveillance data, Italy, 2012 to 2014. Eurosurveillance, 2018, 23, .	3.9	2
67	Evaluation of symptoms suggestive of HIV acute disease among injecting drug users. Journal of Infection, 1995, 30, 263-264.	1.7	1
68	Has Human Immunodeficiency Virus Become More Virulent?. Clinical Infectious Diseases, 2009, 48, 1293-1295.	2.9	1
69	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. International Journal of Cancer, 1999, 82, 334-337.	2.3	1
70	Combined antiretroviral therapy and the incidence of acquired immunodeficiency syndrome-related central nervous system diseases. Annals of Neurology, 2004, 56, 307-307.	2.8	0